Open Trials

At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  As a member of US Oncology Research and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.
 

BREAST CANCER - ADJUVANT

USOR 20-210

Phase 4, Observational Breast Cancer Study for stage I-III hormone receptor-positive (HR+) breast cancer that has taken adjuvant endocrine therapy for 4-7 years. Breast Cancer Index (BCI) Registry Study.

USOR 20-364

Phase 3, randomized, double-blind, placebo-controlled trial with Abemaciclib plus standard adjuvant endocrine therapy for high-risk, node-positive, hormone receptor-positive, HER2 positive early-stage breast cancer who have completed adjuvant HER2 targeted therapy. 

BREAST CANCER – METASTATIC

NRG-BR006

Phase 3, randomized study of Pembrolizumab versus observation in patients with triple-negative breast cancer who have ≥1cm residual disease or positive lymph nodes after neoadjuvant chemotherapy.

COLORECTAL

A021703 (SOLARIS)

Phase 3, randomized, double-blind study of Vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer.

A221805 

Phase 2/3, randomized, double-blind, placebo-controlled study of duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy.

LUNG –  METASTATIC

USOR 19-239

Phase 2, randomized multicenter, double-blind, study of Telaglenastat with Pembrolizumab plus chemotherapy versus placebo with Pembrolizumab plus chemotherapy for first line KEAP1/NRF2 mutated nonsquamous cell NSCLC.

SOLID TUMOR

USOR 21-236

Detecting cancers earlier through elective plasma-based CancerSEEK testing. Patients age 50 years old or greater with untreated solid tumors will undergo one-time blood draw to obtain clinically characterized, whole blood specimens from cancer subjects to develop and refine assays for cancer in the blood.